NRT completes RMB 800 million Series D financing, backed by its pioneering "scarce isotopes + innovative radiopharmaceuticals" model

Chengdu New Radiomedicine Technology Co., Ltd. ("NRT") recently completed approximately 800 million yuan in Series D financing. This round was co-led by Shenzhen Capital Group (SCGC) and PICC Capital, with joint investment from multiple renowned investment firms and financial institutions including China Nuclear Industrial Fund, Wuxi AstraZeneca CICC Venture Capital, Zhongqi Capital, Guangdong Traditional Chinese Medicine Health Equity Investment Fund, Nuclear Power High Tech, Hunan Chasing Fund, and Chengdu Aerotropolis Innovation & Venture Capital. WinX Capital acted as the lead financial advisor.

NRT is a pioneer in medical isotope R&D and production in China, with a strategic portfolio of scarce isotopes already yielding significant results. Its independently developed Galliator™ Gallium-68 Generator has not only gained a solid foothold in the Chinese market but has also successfully expanded into Southeast Asia, laying the foundation for further global expansion. The company has commissioned China's first commercial 30MeV IKON proton cyclotron, poised to achieve independent production and supply of over 10 critical isotopes including Germanium-68 and Actinium-225, bringing its accelerator-driven full industrial chain closer to realization. With ongoing R&D and production of high-demand isotopes such as Radium-223 and Lead-212, NRT is demonstrating its commitment to patient-centric innovation and writing a new chapter for radiopharmaceuticals in China.

NRT has four drug candidates in the clinical stage: NRT6003 injection for liver cancer has entered Phase III trials; NRT6008 injection for pancreatic cancer is undergoing Phase I/II trials; and two radiopharmaceuticals for solid tumors have entered Phase I trials, with Investigational New Drug (IND) approvals secured in both China and the U.S. Additionally, multiple other pipelines are in the preclinical development stage.

Chengdu New Radiomedicine Technology Co., Ltd. ("NRT") has been dedicated to the innovative development, production, and commercialization of medical isotopes and radiopharmaceuticals since its establishment in 2016. 

The company is actively developing a pipeline of innovative products. These include Yttrium-90 Carbon Microspheres Injection and radiolabeled biological molecules such as monoclonal antibodies and peptides. These products are primarily intended for the diagnosis and treatment of prevalent cancers, including liver cancer, pancreatic cancer, lymphoma, thyroid cancer, prostate cancer, and lung cancer.

NRT has established a world-class base for the R&D and production of medical isotopes and radiopharmaceuticals, as well as for providing high-quality CDMO services. Through strategic collaborations with international pharmaceutical and medical device companies, NRT is accelerating the localized production and operation of cutting-edge radiopharmaceuticals, aiming to deliver superior medical solutions for patients in China and worldwide.